

The future of infusion pump software







Healthcare information is everywhere, but it is not always being used to its fullest capacity. There is still a long way to go for fully integrated healthcare across the care continuum. Despite many advances in the use of patient data, there are several medical devices that are behind in the development process.

Compared to other clinical care devices, data from infusion pumps is still in the early stages of being fully integrated into the electronic medical record. As of 2017, IHS Markit estimated that infusion-related software accounted for 15% of revenues when compared to infusion hardware.



Revenue from infusion pumps will grow at a CAGR of 5.0%from 2017 to 2022, increasing from \$2.00 billion in 2017 to \$2.56 billion in 2022.



The infusion pump market is becoming less focused on the pump technology, and more focused on the associated software. The uptake of products with connectivity capability is now increasing.



The United States accounted for 64.5% of global revenue for infusion software in 2017.



Demand is increasing further as more patients are transferred to lower-acuity wards, where there is less intensive care and a nurse is responsible for several

patients at a time.




The fastest revenue growth for infusion software is projected for the Asia Pacific region, a CAGR of 9.4% from 2017 to 2022.



As reimbursement is reduced or even retracted if preventable, adverse events occur, the need for ensuring the patient is sufficiently monitored and remains safe is heightened. As technology progresses and uptake increases, the efficiency of healthcare is expected to improve.



Drug error reduction software (DERS)



Drug error reduction software (DERS) was by far the

is projected to fall, as demand from other infusion software types, such as interoperability, clinical work-flow and tracking/billing software increases.

DERS includes: drug libraries that store drug names

and dosing limits; bar-coding to ensure patients receive the correct medication; and feedback systems. number of smart pumps that have DERS is still very small in emerging regions. As the infusion pump market becomes more established in these countries, there is great potential for growth.

The United States has led the adoption of software

Compared to the number of pumps being sold, the

that enables clinical care devices to communicate with healthcare information systems and patient electronic medical records. This has been fueled by the Health Information Technology for Economic and Clinical Health (HITECH) Act.




medical record via interoperability software. Interoperability software provides the ability to communicate and exchange data accurately, effectively, securely, and consistently with different information technology systems, software applications, and networks, in various settings. Cybersecurity and perceived risks also continue to be limiting factors in the use of connectivity and

interoperability software; both the United States and United Kingdom have provided guidance on the management of risks to be included in product development.

Further development in infusion technology has enabled infusion systems to connect to the electronic



6.3% from \$230.6 million in 2017 to \$310.7 million in 2022.



million in 2017 to \$25.0 million in 2022, growing at a rate above that of infusion hardware.



Infusion Pumps & Dedicated Sets Report – 2018



also provided. Market size estimates are provided in terms of revenues, unit shipments and average selling price, using a base year of 2016 and forecasts for 2017 through to 2022. This is supported by country market sizing analysis and subregional competitive analysis for both the infusion pump and dedicated infusion pump set markets.



KELLY PATRICK

Research Manager, Healthcare Technology Kelly.patrick@ihsmarkit.com



Copyright © 2018 IHS Markit. All Rights Reserved